Arcellx (ACLX) Change in Accured Expenses (2021 - 2025)
Arcellx (ACLX) recorded quarterly Change in Accured Expenses of $958000.0 in Q4 2025, down 45.35% quarter-over-quarter from $1.8 million in Q3 2025, and down 97.51% on a YoY basis from $38.5 million in Q4 2024.
Arcellx (ACLX) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Arcellx's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $958000.0 for Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 97.51% year-over-year to $958000.0; the TTM figure through Dec 2025 stood at $2.7 million (down 93.66% YoY), while the FY2025 annual figure was $2.7 million, down 93.66% from the prior year.
- Change in Accured Expenses was $958000.0 for Q4 2025 at Arcellx, down from $1.8 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $38.5 million in Q4 2024 to a low of -$23.2 million in Q3 2024.
- Historically, Change in Accured Expenses has averaged $2.9 million across 5 years, with a median of $1.1 million in 2021.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses plunged 2165.78% in 2023, then surged 1946.36% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $1.3 million in 2021, then plunged by 248.74% to -$1.9 million in 2022, then soared by 483.32% to $7.2 million in 2023, then soared by 431.63% to $38.5 million in 2024, then tumbled by 97.51% to $958000.0 in 2025.
- The last three Change in Accured Expenses figures came in at $958000.0 (Q4 2025), $1.8 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 958,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 958,000.00 |
| Dec 31, 2025 | 958,000.00 |
| Sep 30, 2025 | 1.75 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Mar 31, 2025 | 2.24 Mn |
| Mar 31, 2025 | 2.24 Mn |
| Dec 31, 2024 | 38.50 Mn |
| Dec 31, 2024 | 38.50 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | 17.68 Mn |
| Mar 31, 2024 | 17.68 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Sep 30, 2023 | 2.15 Mn |
| Sep 30, 2023 | 2.15 Mn |